Scouring ingredient lists. Carrying an EpiPen. Sitting at the special lunch table at school. These anxiety-ridden measures have become routine for families with severe food allergies, who know it only takes one wrong bite to end up in the emergency room.
Nearly 6 million U.S. children and teens— about 8 percent, or two per classroom — have food allergies. In children, peanut allergy, which can be life-threatening, has gone up more than 21 percent since 2010.
Some of these kids – and adults with severe food allergies — are trying a new treatment. And they’re not waiting around for the Food and Drug Administration to approve it. The treatment, known as oral immunotherapy involves consuming tiny amounts of the trigger food, with gradual increases in dose. Over time the immune system learns to react less vigorously to the allergen.
Because there’s not yet an FDA-approved version of this treatment, most providers don’t yet offer it. So most patients can only get it by enrolling in research studies, of which there are have been dozens in recent years.
When Whitney Block, a clinical research nurse who helped run oral immunotherapy trials at Stanford University, saw that more than 2,000 people were on the waitlist to get into these studies, she decided to start offering it on her own. In 2017, Block opened her own clinic, National Allergy Center, in Redwood City and just launched a second site in southern California.
“What I’ve done and continue to do in research trials I’ve brought out to private practice to make it available to more people,” Block says. Patients have flown to the clinic from the East Coast, and even Bulgaria and the United Arab Emirates.
Block is among a small but growing number of allergists around the U.S. who have begun offering the therapy, without enrolling patients in trials. Just four board-certified allergists offered oral immunotherapy for food allergies in 2010, and the number surpassed 100 by 2017, according to the website OIT 101, which is run by parents who’ve had success with oral immunotherapy and maintains a directory of providers.
The therapy is not a cure. People who get the treatment still have to read labels and cannot eat whatever they want. And the vast majority have to continue the treatments indefinitely to keep their tolerance. For peanut allergy, for instance, they would need to continue to consume roughly one peanut per day.
Yet for many, to be able to tolerate even one or two whole peanuts without symptoms is life-changing. “It provides that additional margin of safety,” says Dr. Brian Vickery, an allergist-immunologist at Emory University. “By undergoing this type of treatment, they can move around in the world with more peace of mind.”
Vickery was the lead author on a paper published in the New England Journal of Medicine, which described encouraging results from a placebo-controlled study of peanut protein capsules developed by Aimmune Therapeutics. While it’s possible for clinicians to offer the treatment simply with commercially-available peanut flour, Aimmune’s product, AR101, offers a standardized dose suitable for rigorous study and FDA approval.
The South San Francisco biopharmaceutical company tested AR101 in 551 peanut allergy sufferers at 66 sites. At the end of the 12-month trial, more than two-thirds of the group taking the active drug were able to tolerate a dose of peanut protein equivalent to about two peanut kernels. Based on Aimmune’s recent results, the company submitted a licensing application to the FDA for its peanut capsules in December. It could be approved in 2019 and approval could lead to broader use of the treatment and to insurance covering it.
DBV Technologies of Montrouge, France, is developing another form of immunotherapy that delivers peanut protein to the immune system through a small skin patch. The company plans to re-submit a licensing application for this product, Viaskin Peanut, in response to the FDA’s request for more data on manufacturing procedures and quality controls.
While these products work their way toward approval, the vast majority of providers are not yet offering oral immunotherapy to their patients, except as part of a research trial. “Physicians are concerned that without FDA approval, if something goes wrong, they’re going to be held liable,” says Dr. Christina Ciaccio, a pediatric allergist at the University of Chicago Medicine.
At a national immunology meeting in San Francisco this Sunday, experts will debate whether the treatment is ready to go mainstream. The “yes” side will be presented by Dr. Richard Wasserman, who started offering the treatment to patients at Dallas Food Allergy Center in July 2008. Since then, the clinic has treated more than 800 people for allergies to 20 foods. “The response of patients and families to oral immunotherapy has been the most rewarding thing I have done in 40 years of medical practice,” Wasserman says.
On the “no” side, Dr. Robert Wood, a pediatric allergist at Johns Hopkins Hospital, who has published a study that noted that the degree and duration of protection offered by immunotherapy is unknown, and that allergic reactions are common during the treatment.
Many families find the therapy stressful. At some points during the regimen, often on days the doses increase, most patients experience skin rashes, itching in the mouth, abdominal pain and other unwelcome side effects. And it doesn’t work for everyone. In the recent trial of Aimmune’s peanut capsules, 10 percent of the participants 17 and under who received the active drug needed rescue epinephrine during the exit food challenge at the end of the study.
“If you have lived your life thinking this stuff is poisonous and can kill you… and now the treatment is in fact … to take a little bit of it in food every day, that’s a difficult thing for people for wrap their heads around, particularly when they start to experience symptoms,” Vickery says.
In addition, immunotherapy requires certain precautions that can hinder daily activity. For instance, patients must avoid exercise, hot showers and anything else that elevates the body temperature for several hours after dosing.
Because of the difficulty of the treatment and the risks, clinicians caution against patients trying this on their own. “There is potential for serious side effects,” warns Block. “You definitely need medical oversight.”
Oral immunotherapy treatment “is not going to be suitable and appropriate for everyone,” says Ciaccio. But she says emerging treatments for food allergies “will continue to be a hot topic.”
“We need more than one – just like we need more than one treatment for diabetes,” she says.
Author: Esther Landhuis is a freelance science journalist.